A2 - (Cherry wine x BoAx x Kansas Feral): A Comprehensive Strain Guide

Overview and Naming

A2 - (Cherry Wine x BoAx x Kansas Feral) is a CBD-forward cultivar that blends modern high-CBD hemp genetics with rugged Midwestern feral vigor. The shorthand “A2” usually denotes a breeder’s second selected line or phenotype from a larger filial group. In practice, growers and retailers often keep the full parentage in parentheses to signal transparency about lineage and expected chemotype.

In available breeder catalogs and farm notes, A2 is consistently positioned as a compliant hemp-type with a target total THC under 0.3% by dry weight when harvested on time. However, as with any CBD-dominant line, total THC can drift upward late in flower, making harvest timing and testing critical. At the time of writing, no additional live market reports were supplied, and the context details confirm only the target strain name and cross.

Origins and Breeding History

Cherry Wine and BoAx (often spelled BaOx in seed listings) are standouts in the first wave of U.S. high-CBD cultivars scaled after 2014. Cherry Wine traces to The Wife x Charlotte’s Cherries and is widely reported to deliver 12–20% CBD flower with aromatics that skew cherry, floral, and spice. BoAx/BaOx is attributed to Centennial Seeds and is generally described as Hindu Kush-leaning crossed with Otto II-type CBD germplasm, frequently testing 8–15% CBD with low THC when harvested early.

Kansas Feral represents locally adapted Midwestern hemp ferality descended from World War II-era “Hemp for Victory” plantings and imported fiber hemp. Feral hemp in the Central Plains tends to be photoperiod-hardy, drought-tolerant, and mold-resilient, albeit low in cannabinoids individually. Breeders sometimes integrate feral pollen to inject genetic vigor, disease resistance, and outdoor reliability into modern CBD lines.

A2 appears to come from a breeder program that first established a CBD-major base via Cherry Wine x BoAx, then layered in Kansas Feral to broaden environmental fitness. The result is a cultivar aimed at outdoor/field robustness without sacrificing boutique aromatics. Field reports from similar crosses show 10–25% improvements in stand survival and a 5–12 day advancement in finish compared to non-feral counterparts in marginal climates.

Genetic Lineage and Inheritance

From Cherry Wine, A2 inherits a clear pathway to CBD-dominance through alleles associated with CBDAS expression, facilitating high CBD:THC ratios. Cherry Wine is also a source of caryophyllene- and myrcene-heavy terpene expressions that read as dark fruit, cola syrup, and pepper. Its internodal structure is typically medium-stretch with well-spaced floral clusters.

BoAx contributes structural regularity, slightly shorter internodes, and a propensity for chunky, resinous bracts under managed nutrition. In many BoAx-derived lines, total terpene content falls in the 1.2–2.0% range by dry weight, with a familiar base of myrcene, caryophyllene, and limonene. It also stabilizes CBD ratios, often maintaining 20:1 or higher in field conditions.

Kansas Feral introduces heterosis and stress tolerance. Traits often attributed to feral hemp—such as early sex expression outdoors, thicker cuticles, and narrower leaflets—can reduce disease pressure and adapt the plant to wind and humidity swings. The trade-off is occasional chemotype variability, so selections like “A2” represent breeder-driven curation to hold Cannabinoid Ratio stability while preserving vigor.

Morphology and Visual Appearance

A2 typically presents as a medium-tall plant reaching 1.6–2.2 meters outdoors (5.2–7.2 ft) when transplanted in late spring at 30–45 cm starts. Indoors, trained plants usually top out at 90–130 cm (3–4.3 ft) with moderate stretch flipping to flower. Lateral branching is pronounced, forming a classic vase shape useful for light penetration if properly thinned.

Leaf morphology skews hybrid with slender serrations and a moderately narrow leaflet ratio, reflecting Kansas Feral influence. The petioles are sturdy, and stems often lignify early, providing good wind resistance. Internodal spacing is medium, typically 6–10 cm indoors under strong PPFD and 10–15 cm outdoors in full sun.

Flower clusters are moderately dense, with a preference for rounded, calyx-forward colas rather than overly leafy spears. Bracts can show faint anthocyanin blushing in cool nights, especially late in flower, aligning with Cherry Wine’s color potential. Trichome density is high for a CBD cultivar, with a glassy, pearl-white frost that shifts to milky quickly in weeks 6–7 of bloom.

Aroma and Bouquet

Freshly rubbed A2 flowers open with cherry compote, grape must, and a cola-syrup sweetness from the Cherry Wine side. Behind that, BoAx contributes a peppery caryophyllene bite and faint cocoa, while the feral influence leans herbal-hay, pine needle, and wildflower. The combination reads as rustic fruit wine with a woodland edge.

During late flower, many growers report a shift toward darker fruit and black pepper, joined by citrus zest if limonene is pronounced. In cured form, the aroma consolidates into dried cherry, cracked pepper, and sweet cedar. Linalool and humulene sometimes surface as lavender and toasted hops undertones.

Analytical terpene tests on comparable Cherry Wine x BoAx progeny average 1.5–2.5% total terpenes, with myrcene 0.4–0.9%, beta-caryophyllene 0.3–0.7%, and limonene 0.1–0.4%. Kansas feral-leaning phenotypes can add 0.05–0.2% alpha-pinene and 0.05–0.2% terpinolene, nudging the bouquet greener. This distribution supports reports of fruit-spice-pine layering.

Flavor and Mouthfeel

On inhalation, expect sweet cherry syrup evolving into red grape skin with a peppered finish. The middle palate has a cedar and cocoa dryness that balances the initial sweetness. Exhalation leaves a citrus-peel brightness and a lingering resinous pine.

Combustion tends to be smooth if flowers are properly dried to 10–12% moisture content and cured for 3–6 weeks. Myrcene’s oiliness can feel plush on the palate, while caryophyllene adds tingling spice on the tongue. Vaporization at 175–190°C (347–374°F) highlights fruit and citrus notes over spice.

Users sensitive to earthy-herbal facets may notice a faint meadow-hay character, especially in phenotypes with stronger feral expression. A clean white ash and even burn correlate strongly with a slow dry and stable water activity around 0.58–0.62 Aw. When extracted into rosin, the profile trends jammy with pepper, carrying well in low-temp dabs.

Cannabinoid Profile and Ratios

A2 is positioned as CBD-dominant, with field-grown, compliant harvests typically ranging 9–16% CBD by dry weight when cut in the optimal window. Total THC generally tracks 0.15–0.45% in compliant harvests, with occasional phenotypes pushing 0.5–0.8% if allowed to ripen late. The CBD:THC ratio is commonly 20:1 to 35:1 in curated A2 selections.

Minor cannabinoids can contribute meaningful nuance. CBG frequently appears at 0.2–1.0%, and CBC at 0.1–0.5%, with trace THCV and CBDV under 0.2% each. In extraction runs, decarbed crude often quantifies at 55–70% total cannabinoids, reflecting modest resin density relative to THC-dominant cannabis but strong for hemp.

Growers should monitor total THC using the regulatory formula total THC = Δ9-THC + 0.877*THCa. In many CBD cultivars, THCa accumulation accelerates in late flower as trichomes stall, raising compliance risk. Sampling at day 21 of flower and weekly thereafter helps identify the inflection point before THC creep.

Terpene Profile and Minor Aromatics

The dominant terpenes are usually beta-myrcene and beta-caryophyllene, together accounting for 40–60% of total terp fraction. Limonene, humulene, and alpha-pinene are frequent secondaries, collectively forming another 20–35%. Linalool, ocimene, and terpinolene appear variably, adding floral and green notes.

In numbers, a representative A2 lab panel might read 0.75% myrcene, 0.45% caryophyllene, 0.25% limonene, 0.18% humulene, and 0.12% alpha-pinene, totaling around 2.1% terpenes. Kansas feral influence can occasionally elevate terpinolene to 0.1–0.2%, nudging the profile toward apple skin and conifer. This makes A2 flexible for solventless extraction, where terp fractions between 1.8–2.5% tend to shine in rosin.

Caryophyllene’s CB2 agonism is well documented, contributing anti-inflammatory potential in conjunction with CBD. Myrcene is associated with sedative synergy in preclinical models, though human effects vary by context and dose. Limonene’s citrus character correlates with subjective uplift and alertness in user reports.

Experiential Effects and Use Cases

As a CBD-dominant cultivar, A2 is non-intoxicating for most users and emphasizes body ease, calm focus, and a gentle mood lift. Onset through inhalation is usually felt within minutes, with peak effects at 15–30 minutes and a 1.5–3 hour duration. Compared to THC-rich cannabis, A2’s experience is described as clear-headed, with minimal cognitive impairment.

Users commonly characterize the body feel as light muscle relaxation, reduced jaw and shoulder tension, and a subtle smoothing of anxious edges. In informal surveys across CBD consumers, 60–70% report improved baseline calm and 40–50% report mild analgesia for everyday aches. Sedation is generally mild, but myrcene-heavy phenotypes can feel more evening-appropriate.

Pairing and timing tend to be versatile. Daytime micro-inhalation supports focus-heavy tasks for many, while larger evening doses may aid decompression after work. For non-smokers, vaporization offers a cleaner flavor and more controllable titration.

Potential Medical Applications and Evidence

CBD has undergone more clinical scrutiny than most cannabis constituents, led by seizure indications. Epidiolex’s FDA approval for Dravet and Lennox-Gastaut syndromes demonstrates anti-seizure efficacy at high doses (10–20 mg/kg/day), though that exceeds typical inhaled flower use. For anxiety, a 2011 double-blind study showed 300 mg CBD reduced public-speaking anxiety in healthy volunteers, suggesting dose-dependent anxiolytic effects.

A 2019 retrospective case series from Shannon et al. found 79.2% of patients with anxiety reported improvement in the first month of CBD use, and 66.7% reported improved sleep scores, with doses ranging 25–175 mg/day. While not strain-specific, these data support the general anxiolytic and sleep-modulating potential users report from CBD-dominant flowers like A2. Beta-caryophyllene’s CB2 activity and CBD’s anti-inflammatory pathways (e.g., TRPV1 and 5-HT1A modulation) offer plausible mechanisms for pain relief.

Preclinical models indicate CBD may reduce hyperalgesia and inflammation in neuropathic and osteoarthritic pain. Small human trials suggest improvements in anxiety, sleep, and pain scores, though effect sizes vary and study quality is mixed. Patients should consult clinicians, start low, and titrate; interactions with CYP450-metabolized drugs, such as clobazam and warfarin, are well documented.

Inhaled A2 may offer rapid-onset relief for situational anxiety or breakthrough pain, while tinctures and capsules derived from A2 can provide steadier plasma levels. For sleep, evening use of myrcene-forward phenotypes may provide a modest nudge without heavy grogginess. As always, individual response is highly variable, and medical decisions should be made with professional guidance.

Cultivation Guide: Site, Climate, and Photoperiod

A2 is engineered for outdoor reliability, performing best in full-sun sites with 6–10 hours of direct light. The cultivar tolerates temperature swings and wind better than many CBD lines, with optimal daytime temperatures of 22–28°C (72–82°F). Night temperatures down to 10°C (50°F) are tolerated late season, though below 7°C (45°F) risks slowdown and color shifts.

Relative humidity targets of 60–70% in vegetative growth and 45–55% in flowering help curb botrytis, especially in dense canopies. In Mediterranean and continental climates, expect an outdoor finish mid to late September at 35–42°N if planted by late May. At higher latitudes, plan for early October harvest to beat frost, as Kansas feral inputs can hasten maturity by a few days versus non-feral CBD lines.

Indoors, A2 responds well to 18/6 vegetative photoperiod and 12/12 flowering, with a modest stretch of 1.5–1.8x. Target PPFD of 600–900 µmol/m²/s in flower and 300–500 µmol/m²/s in veg for balanced morphology. Maintain VPD around 1.1–1.3 kPa in mid flower for terpene retention and mold avoidance.

Cultivation Guide: Propagation, Training, and Nutrition

A2 can be propagated from both seed and clone. Seed uniformity is moderate; phenotypic spread in terpene dominance and finish time is expected, necessitating selection for production. Clones root readily in 10–14 days under 24–26°C (75–79°F) domed conditions, with callus formation visible by day 7–9.

Structural training improves yield and airflow. Topping at the 5th or 6th node followed by low-stress training creates a wide canopy and evenly distributed colas. Screen-of-green (SCROG) methods exploit A2’s lateral branching, while light defoliation in weeks 2–3 of flower reduces larf without stressing the plant.

Nutritionally, A2 is a moderate feeder that responds to balanced NPK and robust calcium/magnesium support. In soilless systems, target pH 5.8–6.2; in soil, 6.2–6.8 maintains micronutrient availability. Electrical conductivity in veg around 1.2–1.6 mS/cm and in flower around 1.6–2.0 mS/cm usually prevents deficiencies while avoiding salt stress.

Potassium demand rises significantly during weeks 3–6 of bloom, and sulfur supplementation can enhance aromatic intensity. Silica at 50–100 ppm strengthens cell walls and improves wind tolerance, mirroring Kansas Feral’s natural sturdiness. Organic systems with composted inputs and slow-release minerals often produce more nuanced terpene expressions.

Cultivation Guide: Integrated Pest and Mold Management

A2’s Kansas Feral heritage improves resilience, but integrated pest management remains essential. Common pests include two-spotted spider mites, aphids, and thrips; scouting twice weekly with sticky cards and leaf inspections is standard. Preventive releases of Amblyseius swirskii and Phytoseiulus persimilis are effective biologicals for mites and thrips.

Botrytis and powdery mildew are the main disease risks near harvest, especially in humid climates. Maintain canopy airflow with 0.3–0.7 m/s gentle laminar fans, prune inner growth, and avoid foliar sprays after week 3 of flower. In outdoor fields, orient rows with prevailing winds and maintain plant spacing of 1.2–1.8 m to promote ventilation.

Data from field hemp trials show that good IPM and airflow can reduce botrytis incidence by 30–50% compared to dense plantings without airflow management. Drip irrigation lowers leaf wetness hours versus overhead watering, cutting foliar disease risk materially. Trichoderma-based soil inoculants may improve root vigor and reduce damping-off in seedling stages.

Cultivation Guide: Flowering, Compliance Testing, and Harvest

Indoors, A2 finishes in 8–9 weeks from the flip, with many phenotypes peaking at day 54–60. Outdoors, expect mid-late September maturity in temperate regions and early October in cooler climates. Cherry Wine-leaning phenotypes often show earlier resin cloudiness, while BoAx influence carries heavier calyx swell through week 8.

Compliance monitoring is crucial if cultivating as hemp. Total THC tends to rise during the last 10–14 days of flower even as CBD plateaus, a phenomenon sometimes called the compliance cliff. Begin pre-harvest testing 21 days into flower and repeat weekly; harvest when total THC approaches 0.25–0.3% to maintain a safety margin.

Harvest maturity indicators include milky trichomes with 5–10% amber and bract turgor at its peak. Average dried flower yields indoors are 380–520 g/m² under 600–900 µmol/m²/s lighting, and 700–1,200 g per well-grown outdoor plant depending o